Obat yang dirancang oleh AI untuk IBD baru saja diberikan kepada subjek manusia untuk pertama kalinya.
Absci founder and CEO Sean McClain is thrilled about the company’s transition to a clinical-stage biotech firm, particularly in terms of AI drug discovery. Artificial intelligence has been gradually making its way into drug development, but with limited success in overhauling the complex process. While some drugs have utilized AI in various capacities, none have … Baca Selengkapnya